BioAge Total Current Liabilities from 2010 to 2025
| BIOA Stock | 3.82 0.06 1.55% |
Total Current Liabilities | First Reported 2013-03-31 | Previous Quarter 19.1 M | Current Value 27.8 M | Quarterly Volatility 11.8 M |
Check BioAge Labs, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAge Labs,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 138.5 K, Interest Expense of 3.6 M or Selling General Administrative of 10.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.2. BioAge financial statements analysis is a perfect complement when working with BioAge Labs, Valuation or Volatility modules.
BioAge | Total Current Liabilities |
Latest BioAge Labs,'s Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of BioAge Labs, over the last few years. Total Current Liabilities is an item on BioAge Labs, balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of BioAge Labs, are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. BioAge Labs,'s Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioAge Labs,'s overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
BioAge Total Current Liabilities Regression Statistics
| Arithmetic Mean | 20,360,464 | |
| Geometric Mean | 15,557,142 | |
| Coefficient Of Variation | 74.53 | |
| Mean Deviation | 11,468,992 | |
| Median | 17,813,040 | |
| Standard Deviation | 15,174,140 | |
| Sample Variance | 230.3T | |
| Range | 52.3M | |
| R-Value | 0.13 | |
| Mean Square Error | 242.4T | |
| R-Squared | 0.02 | |
| Significance | 0.62 | |
| Slope | 423,200 | |
| Total Sum of Squares | 3453.8T |
BioAge Total Current Liabilities History
About BioAge Labs, Financial Statements
BioAge Labs, stakeholders use historical fundamental indicators, such as BioAge Labs,'s Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although BioAge Labs, investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioAge Labs,'s assets and liabilities are reflected in the revenues and expenses on BioAge Labs,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BioAge Labs,. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 27.8 M | 30.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of BioAge Labs, Correlation against competitors. For information on how to trade BioAge Stock refer to our How to Trade BioAge Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAge Labs,. If investors know BioAge will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAge Labs, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.40) |
The market value of BioAge Labs, is measured differently than its book value, which is the value of BioAge that is recorded on the company's balance sheet. Investors also form their own opinion of BioAge Labs,'s value that differs from its market value or its book value, called intrinsic value, which is BioAge Labs,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAge Labs,'s market value can be influenced by many factors that don't directly affect BioAge Labs,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAge Labs,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAge Labs, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAge Labs,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.